Next-Generation Fast Dissolving Oral Films for Antihypertensive Therapy: Integration of Nanotechnology, Patient-Centric Design, and Personalized Medicine

Hypertension is a major global health challenge, and conventional antihypertensive therapies are often limited by poor patient compliance, swallowing difficulties, and first-pass metabolism. Fast Dissolving Oral Films (FDOFs) offer a promising alternative by providing rapid disintegration, improved bioavailability, and enhanced patient convenience. This review discusses recent advances in FDOFs for antihypertensive therapy, focusing on nanotechnology-based drug delivery systems, patient-centric formulation strategies, and personalized medicine approaches. The integration of nanocarriers, advanced manufacturing technologies, and dose customization has the potential to improve therapeutic efficacy, patient adherence, and treatment outcomes. Furthermore, regulatory considerations and future prospects of next-generation FDOFs are highlighted, emphasizing their role in precision antihypertensive therapy.